美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2023-054 美康生物科技股份有限公司 2023 年半年度募集资金存放与使用情况 的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会发布的《上市公司监管指引第2号——上市公 司募集资金管理和使用的监管要求》和深圳证券交易所颁布的《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《深圳证券交易 所创业板上市公司自律监管指南第2号——公告格式》的相关规定，本公司将2023 年半年度的募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2021]310号文"关于同意美康生物科技 股份有限公司向特定对象发行股票注册的批复"核准，同意公司向特定对象发行 39,999,995股人民币普通股（A股），每股发行价为人民币15.00元，共募集资金人 民币599,999,925.00元。截至2021年3月17日止，公司实际已发行人民币普通股（A 股）39, ...

美康生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美康生物科技股份有限公司（以下简称"公司"）分别于 2023 年 4 月 24 日、 2023 年 5 月 19 日召开第四届董事会第十六次会议及 2022 年年度股东大会，审 议通过了《关于 2023 年度为全资子公司提供担保额度预计的议案》，同意公司 为宁波美康盛达生物科技有限公司（以下简称"盛达生物"）、宁波美康盛德生 物科技有限公司（以下简称"盛德生物"）融资授信提供担保，预计总担保额度 不超过人民币 10,000 万元（含本数）。其中，公司为最近一期资产负债率 70% 以上的全资子公司盛达生物提供担保的额度预计不超过人民币 6,000 万元，公司 为最近一期资产负债率 70%以下的全资子公司盛德生物提供担保的额度预计不 超过人民币 4,000 万元。具体内容详见刊登在中国证监会指定的创业板信息披露 网站上的相关公告（公告编号：2023-026）。 二、担保进展情况 近日，公司与中国民生银行股份有限公司宁波分行签署了《最高额保证合同》， 为上述全资子公司盛达生物 ...

美康生物科技股份有限公司 关于向全资子公司划转相关资产暨增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次划转及增资概述 1、为优化公司管理和业务架构，提高公司整体经营管理效率，美康生物科 技股份有限公司（以下简称"公司"或"美康生物"）拟将其位于宁波市鄞州区 下应街道姜村村处的土地25,307平方米及地上在建建筑物等资产依据评估作价 向全资子公司宁波瑞合院生物科技有限公司（以下简称"宁波瑞合院"）进行增 资。上述事项实施完毕后，宁波瑞合院将成为上述资产的运营主体。 2、2023年8月18日，公司召开第四届董事会第十九次会议，会议审议通过了 《关于向全资子公司划转相关资产暨增资的议案》。根据《深圳证券交易所创业 板股票上市规则》《美康生物科技股份有限公司章程》（以下简称"《公司章程》"） 及公司《对外投资管理制度》等规章制度的相关规定，本次增资事项属于董事会 决策范围，无需提交股东大会审议。 证券代码：300439 证券简称：美康生物 公告编号：2023-055 美康生物科技股份有限公司 3、本次交易属于公司内部划转，不涉及关联交易，不构成《 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 美康生物科技股份有限公司 投资者关系活动记录表 编号：2023-01 投资者关系活动 √特定对象调研 □分析师会议 类别 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 1、网上业绩说明会：通过全景网参会的网上投资者及网友 人员姓名 2、特定对象调研：金元证券 胡凤龙、王光军、王亦林；毫木资本 徐凤仙等 时间 1、网上业绩说明会：2023 年 5 月 12 日（星期五）下午 15:00-17:00 2、特定对象调研：2023 年 5 月 5 日（星期五）下午 14:00-15:00 地点 1、网上业绩说明会：公司通过全景网"投资者关系互动平台" （https://ir.p5w.net）采用网络远程的方式召开业绩说明会 2、特定对象调研：公司会议室召开特定对象调研 上市公司接待人 1、业绩说明会参加人员：董事长邹炳德、总经理兼董事邹继华、 员姓名 独立董事李成艾、财务总监兼董事会秘书熊慧萍、保荐代表人 钟亚桢 2、特定对象调研参加人员：投资者关系主管徐殷笙 公司主要就 2022 年度及 2023 年第一 ...

Revenue and Profit - The company's revenue for Q1 2023 was ¥490,894,873.63, a decrease of 14.99% compared to ¥577,448,213.25 in the same period last year[4] - Net profit attributable to shareholders was ¥71,413,144.40, representing a 2.66% increase from ¥69,561,237.21 year-on-year[4] - The company achieved operating revenue of RMB 490.89 million, a year-on-year decrease of 14.99%, while self-produced product revenue increased by 36.94%[15] - The net profit attributable to shareholders was RMB 71.41 million, a year-on-year increase of 2.66%, and the net profit after deducting non-recurring gains and losses was RMB 56.61 million, up 7.17%[15] - The total profit for the current period is 76,474,872.82, a decrease from 80,181,917.66 in the previous period, representing a decline of approximately 8.5%[28] - The net profit for the current period is 69,653,541.35, an increase from 67,966,450.42 in the previous period, reflecting a growth of about 2.5%[28] Cash Flow and Financial Position - The net cash flow from operating activities improved significantly to ¥60,351,999.25, a 170.60% increase from a negative cash flow of ¥85,484,991.87 in the previous year[4] - Cash and cash equivalents at the end of the period were CNY 773,538,041.68, down from CNY 806,412,812.69 at the beginning of the year[21] - Total current assets decreased to CNY 1,953,598,972.99 from CNY 2,071,549,435.51, reflecting a reduction of approximately 5.7%[21] - Total liabilities decreased to CNY 902,656,201.09 from CNY 1,064,233,390.98, indicating a reduction of about 15.2%[22] - The company's total equity increased to CNY 2,570,393,299.96 from CNY 2,519,443,027.42, showing a growth of approximately 2%[22] - The cash inflow from operating activities totals 587,144,370.21, down from 606,069,599.01 in the previous period[31] - The cash outflow from investing activities is 205,541,105.18, compared to 160,261,855.94 in the previous period, indicating an increase in investment expenditures[31] - The net cash flow from financing activities is -72,062,091.34, a decrease from -4,839,993.00 in the previous period, reflecting increased cash outflows for debt repayment[33] Earnings and Expenses - Basic and diluted earnings per share increased by 5.56% to ¥0.19 from ¥0.18 in the same period last year[4] - The overall gross margin increased by 1.12 percentage points compared to the same period last year due to a higher proportion of self-produced products, which have a higher gross margin than inspection services and agency products[15] - Financial expenses decreased significantly by 96.51% to ¥185,138.93 from ¥5,298,721.95 due to reduced bank borrowings[10] - Research and development expenses for the quarter were CNY 38,701,417.42, up from CNY 35,417,855.98, reflecting a focus on innovation[26] - The tax expenses for the current period are 6,821,331.47, down from 12,215,467.24 in the previous period, showing a reduction of approximately 44%[28] Asset Management and Investments - Total assets decreased by 3.09% to ¥3,473,049,501.05 from ¥3,583,676,418.40 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 2.85% to ¥2,581,656,450.32 from ¥2,510,065,477.78 at the end of the previous year[4] - The balance of accounts receivable decreased compared to the same period last year, leading to a 246.52% reduction in credit impairment losses[15] - The company transferred 51% equity of Inner Mongolia Shengde for a total price of RMB 14.28 million, and will no longer consolidate Inner Mongolia Shengde into its financial statements[18] - The company signed an agreement to transfer 70% equity of Chongqing Runkang Bio-Tech for a total price of RMB 3.045 million, which will impact the company's 2023 profit by approximately RMB 1.98 million[19] - The actual controller, Zou Bingde, transferred 19,149,991 shares (5% of total shares) to Chen Chaohong at a price of RMB 9.35 per share, totaling RMB 179.05 million[16] - As of the report date, the company had received RMB 4.53 million from the equity transfer of Inner Mongolia Shengde[18] - Zou Bingde released 8 million shares from pledge, leaving 11 million shares still pledged[17] Strategic Outlook - The company aims to expand its market presence and enhance product offerings in the upcoming quarters[27]

Financial Performance - The company's operating revenue for 2022 was ¥2,489,086,216.22, representing a 10.55% increase compared to ¥2,251,532,206.94 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥198,527,038.64, up 10.61% from ¥179,488,034.18 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥170,266,305.71, a slight increase of 1.57% from ¥167,626,310.44 in 2021[19]. - The net cash flow from operating activities was ¥564,665,289.18, reflecting a 9.54% increase from ¥515,482,463.26 in the prior year[19]. - The total assets at the end of 2022 were ¥3,583,676,418.40, a decrease of 0.26% from ¥3,593,187,118.77 at the end of 2021[19]. - The net assets attributable to shareholders increased by 6.95% to ¥2,510,065,477.78 from ¥2,347,016,911.96 in 2021[19]. - The basic earnings per share for 2022 were ¥0.52, an increase of 8.33% compared to ¥0.48 in 2021[19]. - The diluted earnings per share also stood at ¥0.52, reflecting the same 8.33% growth from the previous year[19]. - The weighted average return on equity was 8.20%, slightly down from 8.36% in 2021[19]. - The company achieved total revenue of CNY 248,908.62 million, a year-on-year increase of 10.55%[43]. Dividend Distribution - The company plans to distribute a cash dividend of 1.05 CNY per 10 shares to all shareholders, based on a total of 382,999,815 shares[3]. - The company plans to distribute a cash dividend of 1.05 yuan (including tax) for every 10 shares, with a total cash dividend amounting to 40,214,980.58 yuan, which represents 100% of the total profit distribution[156]. - The total number of shares for the dividend distribution is based on 382,999,815 shares, with no stock dividends or capital reserve transfers planned[157]. Market and Industry Insights - The global in vitro diagnostics (IVD) market size reached $127.4 billion in 2022, with a projected growth to $140 billion by 2027 at a CAGR of 2%[29]. - China's IVD market size was approximately $15.5 billion in 2021, reflecting a year-on-year growth of 17.08%[29]. - The independent clinical laboratory (ICL) industry in China has grown from 89 ICLs in 2010 to 1,966 ICLs by June 2021, with a compound annual growth rate (CAGR) of 32.49%[33]. - The market size of the ICL industry (excluding COVID-19 testing) increased from 14.7 billion CNY in 2017 to 22.3 billion CNY in 2021, with an expected CAGR of 18.2% from 2021 to 2026, reaching 51.3 billion CNY[33]. - The domestic in vitro diagnostic market is expected to benefit from accelerated domestic substitution and increased demand due to aging population and rising healthcare spending[32]. Research and Development - R&D investment reached CNY 17,178.37 million, an increase of 14.00% year-on-year, emphasizing the company's commitment to innovation[43]. - The company reported R&D expenditure of ¥171,783,728.65 in 2022, an increase from ¥150,683,995.48 in 2021, representing a growth of 14.05%[79]. - R&D expenditure accounted for 6.90% of total revenue in 2022, up from 6.69% in 2021[79]. - The number of R&D personnel increased to 402 in 2022, a rise of 6.35% from 378 in 2021[78]. - The company has applied for 383 patents in China, with 269 granted, and 15 patents applied for overseas, with 5 granted[83]. Product Development and Innovation - The company is focusing on advanced diagnostic technologies such as molecular diagnostics and chemiluminescent immunoassays, as encouraged by national policies[31]. - The company launched several new products, including specific growth factor test kits and a compact chemiluminescence analyzer, enhancing its product line[44]. - The company is currently conducting clinical trials for several test kits, including those for soluble growth stimulation expressed gene 2 protein and reverse triiodothyronine, which may enhance its diagnostic capabilities[80]. - The company is pursuing regulatory approvals for various hepatitis-related test kits, which could significantly impact its market presence in infectious disease diagnostics[80]. - The company is expanding its product line with new diagnostic tests, including those for infectious diseases and hormone detection, to enhance brand influence[76]. Strategic Focus and Growth Opportunities - The company has identified significant growth opportunities in the emerging markets, driven by increasing healthcare investments and rising per capita medical spending[30]. - The company aims to enhance its market presence through the introduction of new technologies and products in the coming years[81]. - The company plans to enhance its innovation capabilities in in vitro diagnostic reagents, instruments, and raw materials, focusing on new products like the integrated immunoassay machine and mass spectrometry[112]. - The company aims to strengthen its market position in the IVD industry, targeting leadership in biochemical diagnostics and mass spectrometry, as well as pioneering domestic special inspection services[112]. - The company is exploring potential mergers and acquisitions to bolster its competitive edge in the diagnostics market[81]. Compliance and Governance - The company has established a comprehensive governance structure, including a board of directors and various specialized committees, to ensure effective decision-making and oversight[129]. - The company has maintained independence from its controlling shareholders in terms of assets, personnel, and operations, ensuring autonomous business capabilities[131]. - The company will continue to strengthen its compliance and governance practices in line with relevant laws and regulations[130]. - The company has established a comprehensive internal control management system to enhance compliance and governance, ensuring effective oversight of subsidiaries and investments[159]. - The company has implemented a cash dividend distribution that aligns with the company's articles of association and dividend management policies, ensuring transparency and compliance[156]. Legal and Regulatory Matters - The company is involved in significant litigation, with a claim amounting to RMB 53,630,027.29 related to a breach of agreement by a shareholder[190]. - The company has received a civil judgment from the Ningbo Intermediate Court regarding the Wuhan Anhe Rui contract dispute, with the case still under appeal[190]. - The company is actively pursuing legal actions to recover funds from various parties, including a claim for RMB 25,836,925.08 against Wuhan Anhe Rui[190]. - The company has reported that the litigation process is ongoing, with no final judgment reached as of the report date[190]. - The company is facing multiple lawsuits, with the Ningbo Intermediate Court and the Yinzhou District Court handling different cases[190].

证券代码：300439 证券简称：美康生物 公告编号：2023-032 美康生物科技股份有限公司 为便于广大投资者更深入全面地了解公司2022年度经营情况，公司定于2023 年5月12日（星期五）下午15:00－17:00时举行2022年度网上业绩说明会。本次网 上业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互 动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长邹炳德先生、董事兼总经理邹继华先 生、独立董事李成艾女士、财务总监兼董事会秘书熊慧萍女士、保荐代表人钟亚 桢先生。 为提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 12 日（星期五）下午 14:00 前访问（https://ir.p5w.net/zj/），或扫描 下方二维码，进入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投 资者普遍关注的问题进行回答。 欢迎广大投资者积极参与公司 2022 年度网上业绩说明会。 （问题征集专题页面二维码） 1 / 2 美康生物科技股份有限公司 关于举行 2022 年度网上业绩说明会及征 ...

证券代码：300439 证券简称：美康生物 编号： 2015-04 宁波美康生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 中投证券：梅梅 | | | 人员姓名 | 华创证券：宋凯 | | | 时间 | 2015 年 7 月 3 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书周英章先生 | | | 员姓名 | | | | 投资者关系活动 | 1 | 、公司会考虑收购兼并吗？ | | 主要内容介绍 | | 我国体外诊断行业发展较快，但市场集中度较低，中小企业 | | | | 数 ...

证券代码：300439 证券简称：美康生物 宁波美康生物科技股份有限公司 投资者关系活动记录表 编号： 2015-02 | --- | --- | --- | |----------------|-------------------------------|-----------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 天弘基金：郭相博 中国平安：谢昌旭 | | 人员姓名 | | 博时基金：李权胜 万家基金：张胤 | | | | 华宝兴业基金：郎超 博时基金：兰乔 | | | | 博时基金：刘阳 博时基金：孙少锋 | | | 博时基金：葛晨 银河证券：彭珊 | | | | | 民生证券：吴汉靓 银河证券：张金洋 | | | | 东方证券：李峰 盈象资管：党韦华 | | | | 国泰君安：李子波 华泰柏瑞：盛夏 | | | | 国泰基金：方钰涵 银河证 ...

证券代码：300439 证券简称：美康生物 宁波美康生物科技股份有限公司 投资者关系活动记录表 编号： 2015-03 | --- | --- | --- | |----------------|-----------------------------|-------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 诺安基金：罗春蕾 上投摩根：张一甫 | | 人员姓名 | | 工银瑞信：谭冬寒 中邮基金：曹思 | | | | 长安信托：杨小馨 第一财经：罗琦 | | | | 奥博资本：董凯 上海证券：周学宜 | | | | 长江证券：张琎 顺道投资：丁利 | | | | 东方证券：田加强 广发证券：马帅 | | | | 国都证券：姚巍 金元惠理基金：姚宏福 | | | | 汇利资管：叶丽 泰旸资产：彭飞 | | | | 东方证券：张韡 国时 ...